Jiangsu Hengrui Medicine Key Executives
This section highlights Jiangsu Hengrui Medicine 's key executives, including their titles and compensation details.
Find Contacts at Jiangsu Hengrui Medicine
(Showing 0 of )
Jiangsu Hengrui Medicine Earnings
This section highlights Jiangsu Hengrui Medicine 's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
March 31, 2025
Time:
Before Market
Est. EPS:
$0.35
Status:
Unconfirmed
Last Earnings Results
Date:
October 24, 2024
EPS:
$0.19
Est. EPS:
$0.23
Revenue:
$6.59B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Healthcare
Drug Manufacturers - General
$44.85
Stock Price
$284.77B
Market Cap
-
Employees
Lianyungang, None
Location
Financial Statements
Access annual & quarterly financial statements for Jiangsu Hengrui Medicine , including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $22.82B | $21.28B | $25.91B | $27.73B | $23.29B |
| Cost of Revenue | $3.53B | $3.49B | $3.74B | $3.35B | $2.91B |
| Gross Profit | $19.29B | $17.79B | $22.16B | $24.39B | $20.38B |
| Gross Profit Ratio | 84.55% | 83.61% | 85.60% | 87.93% | 87.49% |
| Research and Development Expenses | $4.95B | $4.89B | $5.94B | $4.99B | $3.90B |
| General and Administrative Expenses | $2.29B | $1.75B | $2.06B | $2.23B | $1.55B |
| Selling and Marketing Expenses | $7.58B | $7.35B | $9.38B | $9.80B | $8.52B |
| Selling General and Administrative Expenses | $9.98B | $9.10B | $11.44B | $12.03B | $10.08B |
| Other Expenses | $-584.85M | $458.68M | $697.90M | $888.69M | $717.72M |
| Operating Expenses | $14.38B | $14.44B | $18.08B | $17.91B | $14.69B |
| Cost and Expenses | $17.91B | $17.93B | $21.82B | $21.26B | $17.60B |
| Interest Income | $477.14M | $385.28M | $367.46M | $290.27M | $127.14M |
| Interest Expense | $6.66M | $6.49M | $4.71M | $5.49M | $6.88M |
| Depreciation and Amortization | $793.94M | $644.15M | $540.73M | $475.22M | $645.84M |
| EBITDA | $5.54B | $4.68B | $5.02B | $7.38B | $6.68B |
| EBITDA Ratio | 24.28% | 22.31% | 19.61% | 26.54% | 28.63% |
| Operating Income | $4.91B | $4.11B | $4.66B | $7.01B | $6.15B |
| Operating Income Ratio | 21.52% | 19.33% | 18.01% | 25.26% | 26.41% |
| Total Other Income Expenses Net | $-242.80M | $-143.47M | $-198.51M | $-111.59M | $-93.92M |
| Income Before Tax | $4.67B | $3.97B | $4.47B | $6.90B | $6.06B |
| Income Before Tax Ratio | 20.45% | 18.65% | 17.24% | 24.86% | 26.00% |
| Income Tax Expense | $389.29M | $153.42M | $-17.72M | $586.59M | $729.31M |
| Net Income | $4.30B | $3.91B | $4.53B | $6.33B | $5.33B |
| Net Income Ratio | 18.85% | 18.36% | 17.49% | 22.82% | 22.88% |
| EPS | $0.68 | $0.61 | $0.71 | $1.00 | $0.84 |
| EPS Diluted | $0.68 | $0.61 | $0.71 | $1.00 | $0.84 |
| Weighted Average Shares Outstanding | 6.33B | 6.37B | 6.38B | 6.36B | 6.34B |
| Weighted Average Shares Outstanding Diluted | 6.33B | 6.37B | 6.38B | 6.36B | 6.34B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.59B | $7.55B | $6.00B | $5.81B | $5.85B | $5.68B | $5.49B | $5.33B | $5.72B | $4.75B | $5.48B | $5.71B | $6.90B | $6.37B | $6.93B | $8.32B | $8.10B | $5.78B | $5.53B | $6.34B |
| Cost of Revenue | $959.88M | $1.02B | $942.85M | $867.69M | $888.18M | $909.86M | $859.52M | $817.89M | $980.82M | $832.63M | $855.29M | $1.01B | $974.35M | $843.82M | $910.40M | $964.14M | $1.02B | $622.85M | $740.90M | $740.46M |
| Gross Profit | $5.63B | $6.53B | $5.05B | $4.94B | $4.96B | $4.77B | $4.63B | $4.51B | $4.74B | $3.92B | $4.62B | $4.69B | $5.93B | $5.52B | $6.02B | $7.36B | $7.08B | $5.16B | $4.79B | $5.60B |
| Gross Profit Ratio | 85.43% | 86.50% | 84.30% | 85.10% | 84.80% | 84.00% | 84.40% | 84.70% | 82.80% | 82.50% | 84.40% | 82.20% | 85.90% | 86.80% | 86.90% | 88.41% | 87.40% | 89.23% | 86.59% | 88.33% |
| Research and Development Expenses | $1.51B | $1.75B | $1.22B | $1.23B | $1.39B | $1.18B | $1.15B | $1.39B | $1.31B | $1.18B | $1.01B | $1.80B | $1.56B | $1.26B | $1.32B | $1.64B | $1.48B | $1.05B | $811.20M | $996.86M |
| General and Administrative Expenses | $755.51M | $542.30M | $576.30M | $-265.08M | $1.00B | $126.81M | $545.67M | $282.48M | $903.88M | $5.14M | $559.29M | $516.59M | $777.48M | $132.06M | $629.04M | $342.49M | $830.93M | $529.04M | $495.14M | $29.02M |
| Selling and Marketing Expenses | $3.55B | $2.17B | $1.76B | $2.17B | $1.73B | $2.01B | $1.67B | $2.19B | $1.90B | $1.51B | $1.76B | $2.39B | $2.33B | $2.33B | $2.33B | $2.90B | $2.88B | $2.10B | $1.93B | $2.36B |
| Selling General and Administrative Expenses | $4.31B | $2.78B | $2.34B | $1.90B | $2.73B | $2.14B | $2.22B | $2.47B | $2.80B | $1.51B | $2.32B | $2.90B | $3.11B | $2.47B | $2.96B | $3.24B | $3.71B | $2.63B | $2.42B | $2.39B |
| Other Expenses | $-1.55B | $15.71M | $-133.50M | $-113.84M | $-75.86M | $-33.41M | $26.40M | $502.49M | $-422.66M | $368.50M | $10.35M | $64.96M | $-69.53M | $-46.94M | $-27.75M | $58.32M | $-60.96M | $-51.76M | $-29.61M | $-32.09M |
| Operating Expenses | $4.27B | $4.51B | $3.56B | $3.94B | $3.67B | $3.66B | $3.39B | $4.36B | $3.69B | $3.06B | $3.34B | $5.34B | $4.26B | $4.16B | $4.32B | $5.65B | $5.25B | $3.73B | $3.28B | $4.06B |
| Cost and Expenses | $5.23B | $5.53B | $4.51B | $4.81B | $4.56B | $4.57B | $4.25B | $5.18B | $4.67B | $3.89B | $4.19B | $6.35B | $5.23B | $5.00B | $5.23B | $6.61B | $6.27B | $4.35B | $4.02B | $4.80B |
| Interest Income | $120.13M | $537.25M | $166.46M | $828.00M | $145.82M | $292.19M | $83.84M | $633.94M | $132.77M | $260.31M | $92.62M | $654.57M | $99.31M | $285.10M | $97.30M | $177.88M | $64.60M | $183.63M | $131.97M | $216.17M |
| Interest Expense | $39.22M | $3.31M | $17.83M | $1.16M | $1.06M | $2.70M | $985.81K | $4.44M | $- | $1.07M | $1.35M | $10.52M | $25.93M | $2.95M | $15.28M | $- | $25.10M | $63.47M | $- | $114.23M |
| Depreciation and Amortization | $-25.37M | $212.41M | $163.61M | $222.45M | $222.45M | $174.52M | $174.52M | $165.40M | $165.40M | $156.68M | $156.68M | $144.28M | $144.28M | $128.81M | $128.81M | $112.10M | $154.63M | $128.80M | $154.63M | $154.63M |
| EBITDA | $1.34B | $2.50B | $1.71B | $1.10B | $1.53B | $1.36B | $1.50B | $604.33M | $1.35B | $1.14B | $1.52B | $-306.59M | $1.95B | $1.49B | $1.90B | $1.96B | $1.99B | $1.66B | $1.71B | $1.83B |
| EBITDA Ratio | 20.26% | 29.55% | 24.92% | 16.43% | 22.83% | 21.22% | 24.12% | 11.51% | 20.57% | 20.79% | 25.41% | -4.21% | 23.03% | 23.40% | 24.84% | 25.55% | 22.64% | 28.65% | 27.80% | 30.03% |
| Operating Income | $1.36B | $2.02B | $1.64B | $968.58M | $1.37B | $1.23B | $1.34B | $460.13M | $1.25B | $1.03B | $1.37B | $-408.23M | $1.85B | $1.43B | $1.80B | $1.81B | $1.94B | $1.64B | $1.61B | $1.69B |
| Operating Income Ratio | 20.65% | 26.74% | 27.28% | 16.68% | 23.46% | 21.60% | 24.48% | 8.63% | 21.92% | 21.75% | 24.93% | -7.15% | 26.75% | 22.40% | 25.98% | 21.80% | 23.96% | 28.35% | 29.17% | 26.67% |
| Total Other Income Expenses Net | $-25.37M | $-65.30M | $-133.50M | $-113.84M | $-71.19M | $-38.08M | $-19.68M | $-25.63M | $-71.08M | $-46.45M | $-311.20K | $-54.29M | $-44.75M | $-71.71M | $-27.75M | $40.36M | $-60.96M | $-61.38M | $-29.61M | $-38.26M |
| Income Before Tax | $1.34B | $2.28B | $1.50B | $854.73M | $1.30B | $1.19B | $1.32B | $434.50M | $1.18B | $986.45M | $1.37B | $-462.52M | $1.80B | $1.35B | $1.77B | $1.85B | $1.88B | $1.58B | $1.58B | $1.65B |
| Income Before Tax Ratio | 20.26% | 30.26% | 25.05% | 14.72% | 22.24% | 20.92% | 24.12% | 8.15% | 20.68% | 20.77% | 24.92% | -8.11% | 26.10% | 21.27% | 25.58% | 22.28% | 23.21% | 27.29% | 28.63% | 26.07% |
| Income Tax Expense | $146.94M | $188.45M | $135.02M | $27.94M | $139.31M | $130.68M | $91.36M | $-284.52M | $154.14M | $126.66M | $157.14M | $-754.65M | $271.69M | $188.52M | $276.72M | $-212.01M | $290.96M | $230.96M | $276.68M | $60.66M |
| Net Income | $1.19B | $2.06B | $1.37B | $828.66M | $1.17B | $1.07B | $1.24B | $732.91M | $1.05B | $882.38M | $1.24B | $323.02M | $1.54B | $1.17B | $1.50B | $2.07B | $1.60B | $1.35B | $1.32B | $1.59B |
| Net Income Ratio | 18.03% | 27.34% | 22.82% | 14.27% | 19.94% | 18.84% | 22.56% | 13.75% | 18.44% | 18.58% | 22.58% | 5.66% | 22.31% | 18.39% | 21.60% | 24.87% | 19.70% | 23.29% | 23.80% | 25.11% |
| EPS | $0.19 | $0.32 | $0.21 | $0.13 | $0.18 | $0.17 | $0.19 | $0.12 | $0.17 | $0.14 | $0.19 | $0.05 | $0.24 | $0.18 | $0.23 | $0.32 | $0.25 | $0.21 | $0.21 | $0.25 |
| EPS Diluted | $0.19 | $0.32 | $0.21 | $0.13 | $0.18 | $0.17 | $0.19 | $0.12 | $0.16 | $0.14 | $0.19 | $0.05 | $0.24 | $0.18 | $0.23 | $0.32 | $0.25 | $0.21 | $0.21 | $0.25 |
| Weighted Average Shares Outstanding | 6.35B | 6.35B | 6.52B | 6.35B | 6.36B | 6.36B | 6.37B | 6.37B | 6.20B | 6.33B | 6.38B | 6.38B | 6.37B | 6.20B | 6.36B | 6.39B | 6.39B | 6.41B | 5.44B | 6.35B |
| Weighted Average Shares Outstanding Diluted | 6.35B | 6.35B | 6.52B | 6.35B | 6.36B | 6.36B | 6.37B | 6.37B | 6.51B | 6.51B | 6.51B | 6.40B | 6.39B | 6.39B | 6.51B | 6.39B | 6.39B | 6.53B | 5.44B | 6.35B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $20.75B | $15.11B | $13.63B | $10.80B | $5.04B |
| Short Term Investments | $99.05M | $2.76B | $5.09B | $5.63B | $8.52B |
| Cash and Short Term Investments | $20.85B | $17.87B | $18.72B | $16.43B | $13.56B |
| Net Receivables | $6.13B | $8.34B | $6.88B | $8.18B | $5.43B |
| Inventory | $2.31B | $2.45B | $2.40B | $1.78B | $1.61B |
| Other Current Assets | $1.99B | $2.27B | $2.18B | $1.66B | $1.71B |
| Total Current Assets | $31.29B | $30.93B | $30.19B | $28.05B | $22.31B |
| Property Plant Equipment Net | $6.63B | $6.68B | $6.28B | $4.59B | $4.07B |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $3.38B | $2.20B | $702.44M | $341.25M | $349.76M |
| Goodwill and Intangible Assets | $3.38B | $2.20B | $702.44M | $341.25M | $349.76M |
| Long Term Investments | $1.35B | $-1.25B | $-4.09B | $-4.13B | $-7.92B |
| Tax Assets | $320.56M | $223.03M | $141.36M | $52.97M | $66.09M |
| Other Non-Current Assets | $818.36M | $3.57B | $6.05B | $5.83B | $8.67B |
| Total Non-Current Assets | $12.50B | $11.42B | $9.08B | $6.68B | $5.25B |
| Other Assets | $0 | $1 | $1 | $- | $- |
| Total Assets | $43.78B | $42.36B | $39.27B | $34.73B | $27.56B |
| Account Payables | $1.33B | $1.77B | $2.25B | $1.33B | $1.29B |
| Short Term Debt | $- | $825.24M | $- | $- | $- |
| Tax Payables | $218.97M | $119.18M | $166.36M | $175.76M | $225.08M |
| Deferred Revenue | $198.09M | $187.08M | $219.55M | $358.06M | $220.78M |
| Other Current Liabilities | $802.59M | $304.47M | $982.40M | $2.27B | $737.52M |
| Total Current Liabilities | $2.55B | $3.64B | $3.40B | $3.77B | $2.47B |
| Long Term Debt | $75.18M | $98.86M | $151.59M | $- | $- |
| Deferred Revenue Non-Current | $38.95M | $119.44M | $116.52M | $141.24M | $122.22M |
| Deferred Tax Liabilities Non-Current | $83.64M | $84.33M | $24.77M | $29.76M | $24.09M |
| Other Non-Current Liabilities | $- | $-16.11M | $1 | $- | $- |
| Total Non-Current Liabilities | $197.76M | $302.63M | $292.88M | $170.99M | $146.31M |
| Other Liabilities | $-7 | $1 | $- | $- | $- |
| Total Liabilities | $2.75B | $3.94B | $3.69B | $3.94B | $2.62B |
| Preferred Stock | $- | $- | $- | $- | $1 |
| Common Stock | $6.38B | $6.38B | $6.40B | $5.33B | $4.42B |
| Retained Earnings | $28.80B | $25.52B | $22.87B | $20.84B | $16.55B |
| Accumulated Other Comprehensive Income Loss | $19.32M | $2.94B | $3.03B | $1.79B | $2.48B |
| Other Total Stockholders Equity | $5.26B | $5.92B | $5.73B | $2.54B | $3.80B |
| Total Stockholders Equity | $40.47B | $37.82B | $35.00B | $30.50B | $24.78B |
| Total Equity | $41.03B | $38.41B | $35.57B | $30.79B | $24.94B |
| Total Liabilities and Stockholders Equity | $43.78B | $42.36B | $39.27B | $34.73B | $27.56B |
| Minority Interest | $567.29M | $589.35M | $568.85M | $282.70M | $162.20M |
| Total Liabilities and Total Equity | $43.78B | $42.36B | $39.27B | $34.73B | $27.56B |
| Total Investments | $1.45B | $1.51B | $1.00B | $1.50B | $599.43M |
| Total Debt | $75.18M | $1.36B | $151.59M | $1.60B | $419.84M |
| Net Debt | $-20.67B | $-13.75B | $-13.48B | $-9.20B | $-4.62B |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $22.13B | $22.31B | $21.31B | $20.75B | $17.41B | $16.14B | $14.23B | $15.11B | $16.00B | $13.42B | $13.61B | $13.63B | $14.33B | $12.51B | $12.57B | $10.80B | $11.05B | $9.56B | $8.77B | $5.04B |
| Short Term Investments | $773.72M | $973.23M | $466.41M | $99.05M | $209.54M | $821.53M | $1.74B | $2.76B | $2.05B | $5.08B | $4.41B | $5.09B | $3.36B | $4.14B | $3.77B | $5.63B | $4.67B | $5.84B | $6.24B | $8.52B |
| Cash and Short Term Investments | $22.91B | $23.29B | $21.77B | $20.85B | $17.62B | $16.96B | $15.98B | $17.87B | $18.05B | $18.50B | $18.01B | $18.72B | $17.70B | $16.65B | $16.34B | $16.43B | $15.72B | $15.41B | $15.01B | $13.56B |
| Net Receivables | $7.36B | $6.93B | $7.84B | $6.13B | $8.65B | $7.89B | $9.96B | $8.34B | $7.51B | $7.96B | $7.55B | $6.88B | $8.37B | $8.34B | $8.80B | $8.18B | $7.37B | $4.45B | $6.17B | $5.43B |
| Inventory | $2.53B | $2.25B | $2.27B | $2.31B | $2.48B | $2.41B | $2.54B | $2.45B | $2.30B | $2.39B | $2.62B | $2.40B | $2.29B | $2.35B | $2.04B | $1.78B | $1.74B | $1.94B | $1.74B | $1.61B |
| Other Current Assets | $1.66B | $2.31B | $1.83B | $1.99B | $1.89B | $2.63B | $2.17B | $2.27B | $1.75B | $2.05B | $2.32B | $2.18B | $2.00B | $2.24B | $2.05B | $1.66B | $1.52B | $1.98B | $7.07B | $1.71B |
| Total Current Assets | $34.46B | $34.78B | $33.71B | $31.29B | $30.63B | $29.89B | $30.65B | $30.93B | $29.62B | $30.90B | $30.49B | $30.19B | $30.36B | $29.58B | $29.24B | $28.05B | $25.57B | $23.78B | $23.82B | $22.31B |
| Property Plant Equipment Net | $6.69B | $6.83B | $6.57B | $6.63B | $6.70B | $6.69B | $6.65B | $6.68B | $6.58B | $6.43B | $6.46B | $6.28B | $5.76B | $5.26B | $4.79B | $4.59B | $4.29B | $4.16B | $4.07B | $4.07B |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $4.61B | $4.18B | $3.68B | $3.38B | $3.13B | $2.92B | $2.47B | $2.20B | $1.85B | $1.48B | $1.16B | $702.44M | $437.68M | $328.14M | $338.98M | $341.25M | $343.02M | $345.27M | $347.52M | $349.76M |
| Goodwill and Intangible Assets | $4.61B | $4.18B | $3.68B | $3.38B | $3.13B | $2.92B | $2.47B | $2.20B | $1.85B | $1.48B | $1.16B | $702.44M | $437.68M | $328.14M | $338.98M | $341.25M | $343.02M | $345.27M | $347.52M | $349.76M |
| Long Term Investments | $1.47B | $1.50B | $802.67M | $1.35B | $1.26B | $655.50M | $-234.92M | $-1.25B | $-923.28M | $-4.27B | $-3.77B | $-4.09B | $-1.34B | $-2.61B | $-2.24B | $-4.13B | $-2.59B | $-4.68B | $-5.52B | $-7.92B |
| Tax Assets | $413.25M | $404.34M | $365.86M | $320.56M | $189.36M | $218.08M | $224.68M | $223.03M | $164.19M | $190.93M | $175.32M | $141.36M | $58.00M | $58.40M | $52.88M | $52.97M | $71.52M | $65.90M | $71.55M | $66.09M |
| Other Non-Current Assets | $703.18M | $498.22M | $1.20B | $818.36M | $962.21M | $1.59B | $2.53B | $3.57B | $2.89B | $6.01B | $5.31B | $6.05B | $3.67B | $4.38B | $3.97B | $5.83B | $4.85B | $6.00B | $6.39B | $8.67B |
| Total Non-Current Assets | $13.88B | $13.40B | $12.63B | $12.50B | $12.24B | $12.07B | $11.64B | $11.42B | $10.56B | $9.84B | $9.32B | $9.08B | $8.59B | $7.42B | $6.92B | $6.68B | $6.97B | $5.90B | $5.35B | $5.25B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $1 | $- | $1 | $1 | $- | $- | $- | $- | $1 | $- | $- |
| Total Assets | $48.34B | $48.18B | $46.34B | $43.78B | $42.87B | $41.96B | $42.29B | $42.36B | $40.18B | $40.75B | $39.82B | $39.27B | $38.95B | $37.00B | $36.16B | $34.73B | $32.54B | $29.68B | $29.17B | $27.56B |
| Account Payables | $1.54B | $1.44B | $1.46B | $1.33B | $1.66B | $1.46B | $1.88B | $1.77B | $1.71B | $1.42B | $2.05B | $2.25B | $1.89B | $1.53B | $1.15B | $1.33B | $1.48B | $1.48B | $1.39B | $1.29B |
| Short Term Debt | $- | $- | $- | $- | $16.10M | $10.00M | $10.00M | $825.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $356.04M | $112.05M | $249.30M | $218.97M | $223.46M | $244.46M | $182.38M | $119.18M | $137.35M | $165.47M | $322.60M | $166.36M | $478.62M | $138.88M | $237.67M | $175.76M | $682.26M | $260.02M | $276.82M | $225.08M |
| Deferred Revenue | $- | $1.23B | $1.45B | $198.09M | $751.82M | $782.50M | $199.75M | $187.08M | $305.95M | $206.15M | $177.22M | $219.55M | $171.29M | $346.62M | $389.09M | $- | $- | $- | $- | $- |
| Other Current Liabilities | $1.93B | $2.03B | $538.68M | $802.59M | $356.35M | $333.13M | $260.88M | $304.47M | $424.02M | $2.05B | $373.66M | $982.40M | $1.57B | $1.72B | $1.68B | $2.27B | $1.76B | $1.03B | $1.07B | $958.30M |
| Total Current Liabilities | $3.83B | $4.81B | $3.70B | $2.55B | $2.45B | $2.26B | $2.54B | $3.64B | $2.58B | $3.84B | $2.75B | $3.40B | $3.94B | $3.39B | $3.46B | $3.77B | $3.92B | $2.78B | $2.74B | $2.47B |
| Long Term Debt | $51.30M | $15.73M | $78.40M | $75.18M | $73.78M | $76.88M | $83.91M | $98.86M | $147.28M | $131.67M | $143.75M | $151.59M | $49.97M | $51.79M | $47.18M | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $42.55M | $42.55M | $38.95M | $38.95M | $68.22M | $109.44M | $120.34M | $119.44M | $116.52M | $116.52M | $116.52M | $116.52M | $120.95M | $156.06M | $151.98M | $141.24M | $188.40M | $167.38M | $135.95M | $122.22M |
| Deferred Tax Liabilities Non-Current | $83.16M | $85.09M | $85.23M | $83.64M | $77.65M | $79.18M | $78.78M | $84.33M | $20.27M | $25.16M | $23.73M | $24.77M | $19.06M | $27.16M | $29.85M | $29.76M | $22.48M | $20.27M | $21.56M | $24.09M |
| Other Non-Current Liabilities | $- | $-42.55M | $- | $- | $- | $- | $- | $103.33M | $1 | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $177.01M | $143.37M | $202.57M | $197.76M | $219.65M | $265.50M | $283.03M | $302.63M | $284.07M | $273.36M | $284.00M | $292.88M | $189.98M | $235.00M | $229.01M | $170.99M | $210.87M | $187.66M | $157.51M | $146.31M |
| Other Liabilities | $0 | $0 | $- | $- | $1 | $- | $- | $1 | $1 | $- | $1 | $- | $1 | $1 | $1 | $- | $1 | $1 | $- | $- |
| Total Liabilities | $4.01B | $4.95B | $3.90B | $2.75B | $2.66B | $2.53B | $2.82B | $3.94B | $2.87B | $4.11B | $3.03B | $3.69B | $4.13B | $3.62B | $3.69B | $3.94B | $4.13B | $2.96B | $2.90B | $2.62B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.79M | $- | $1 | $- | $1 |
| Common Stock | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.38B | $6.40B | $6.40B | $6.40B | $5.33B | $5.33B | $5.31B | $5.31B | $4.42B | $4.42B |
| Retained Earnings | $32.15B | $30.96B | $30.17B | $28.80B | $27.97B | $26.81B | $26.76B | $25.52B | $25.03B | $23.98B | $24.11B | $22.87B | $22.92B | $21.38B | $22.34B | $20.84B | $18.90B | $17.31B | $17.86B | $16.55B |
| Accumulated Other Comprehensive Income Loss | $6.53B | $3.50B | $6.42B | $3.39B | $6.48B | $3.45B | $6.35B | $3.33B | $5.74B | $3.04B | $5.75B | $3.69B | $6.09B | $3.72B | $6.01B | $-4.79M | $58.59K | $10.69M | $11.69M | $6.53M |
| Other Total Stockholders Equity | $-1.29B | $1.79B | $-1.10B | $5.26B | $5.27B | $2.22B | $5.75B | $2.59B | $-398.03M | $2.67B | $1 | $5.73B | $4.92B | $5.01B | $-1.50B | $4.33B | $4.03B | $1.12B | $3.82B | $907.62M |
| Total Stockholders Equity | $43.77B | $42.62B | $41.87B | $40.47B | $39.64B | $38.86B | $38.89B | $37.82B | $36.75B | $36.07B | $36.24B | $35.00B | $34.24B | $32.79B | $32.19B | $30.50B | $28.25B | $26.55B | $26.12B | $24.78B |
| Total Equity | $44.33B | $43.19B | $42.44B | $41.03B | $40.21B | $39.44B | $39.47B | $38.41B | $37.31B | $36.64B | $36.78B | $35.57B | $34.82B | $33.38B | $32.47B | $30.79B | $28.41B | $26.71B | $26.27B | $24.94B |
| Total Liabilities and Stockholders Equity | $48.34B | $48.18B | $46.34B | $43.78B | $42.87B | $41.96B | $42.29B | $42.36B | $40.18B | $40.75B | $39.82B | $39.27B | $38.95B | $37.00B | $36.16B | $34.73B | $32.54B | $29.68B | $29.17B | $27.56B |
| Minority Interest | $563.61M | $564.89M | $565.85M | $567.29M | $569.69M | $575.26M | $582.27M | $589.35M | $556.67M | $566.92M | $540.06M | $568.85M | $581.92M | $591.92M | $282.49M | $282.70M | $158.95M | $165.73M | $152.94M | $162.20M |
| Total Liabilities and Total Equity | $48.34B | $48.18B | $46.34B | $43.78B | $42.87B | $41.96B | $42.29B | $42.36B | $40.18B | $40.75B | $39.82B | $39.27B | $38.95B | $37.00B | $36.16B | $34.73B | $32.54B | $29.68B | $29.17B | $27.56B |
| Total Investments | $1.47B | $2.47B | $1.27B | $1.45B | $1.47B | $1.48B | $1.51B | $1.51B | $1.13B | $816.19M | $637.58M | $1.00B | $2.02B | $1.53B | $1.53B | $1.50B | $2.08B | $1.17B | $711.61M | $599.43M |
| Total Debt | $51.30M | $487.56M | $78.40M | $75.18M | $89.88M | $86.88M | $93.91M | $1.36B | $147.28M | $131.67M | $143.75M | $151.59M | $49.97M | $51.79M | $47.18M | $- | $- | $- | $- | $- |
| Net Debt | $-22.08B | $-21.82B | $-21.23B | $-20.67B | $-17.32B | $-16.05B | $-14.14B | $-13.75B | $-15.85B | $-13.29B | $-13.46B | $-13.48B | $-14.28B | $-12.46B | $-12.52B | $-10.80B | $-11.05B | $-9.56B | $-8.77B | $-5.04B |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $4.28B | $3.82B | $4.48B | $6.31B | $5.33B |
| Depreciation and Amortization | $704.64M | $577.89M | $520.41M | $448.39M | $618.52M |
| Deferred Income Tax | $- | $-22.11M | $-93.38M | $18.79M | $46.56M |
| Stock Based Compensation | $- | $29.20M | $143.80M | $312.82M | $184.42M |
| Change in Working Capital | $2.38B | $-2.87B | $-783.17M | $-3.42B | $-2.01B |
| Accounts Receivables | $2.04B | $-2.28B | $-868.27M | $-3.49B | $-2.89B |
| Inventory | $129.11M | $-52.68M | $-631.22M | $-173.62M | $-581.70M |
| Accounts Payables | $315.32M | $-510.98M | $809.70M | $222.12M | $1.42B |
| Other Working Capital | $-98.47M | $-22.11M | $-93.38M | $18.79M | $46.56M |
| Other Non Cash Items | $279.31M | $-267.32M | $-52.87M | $-237.85M | $-348.99M |
| Net Cash Provided by Operating Activities | $7.64B | $1.27B | $4.22B | $3.43B | $3.82B |
| Investments in Property Plant and Equipment | $-1.48B | $-1.99B | $-1.66B | $-554.33M | $-561.35M |
| Acquisitions Net | $20.18M | $36.05M | $358.11M | $557.88M | $562.55M |
| Purchases of Investments | $-17.09M | $-7.44B | $-13.20B | $-27.64B | $-28.57B |
| Sales Maturities of Investments | $2.61B | $9.77B | $14.30B | $29.99B | $27.18B |
| Other Investing Activities | $95.51M | $20.21M | $-342.00M | $-554.33M | $-561.35M |
| Net Cash Used for Investing Activities | $1.22B | $390.29M | $-546.26M | $1.80B | $-1.95B |
| Debt Repayment | $-1.26B | $1.26B | $- | $- | $- |
| Common Stock Issued | $- | $-861.97M | $305.13M | $- | $- |
| Common Stock Repurchased | $-827.26M | $-398.03M | $-274.08M | $-11.98M | $-4.63M |
| Dividends Paid | $-1.02B | $-1.01B | $-1.07B | $-1.02B | $-810.89M |
| Other Financing Activities | $-37.29M | $-942.84M | $67.92M | $1.31B | $97.01M |
| Net Cash Used Provided by Financing Activities | $-3.14B | $-318.77M | $-998.32M | $291.19M | $-718.51M |
| Effect of Forex Changes on Cash | $12.53M | $80.50M | $-16.87M | $-89.08M | $12.31M |
| Net Change in Cash | $5.73B | $1.42B | $2.66B | $5.43B | $1.17B |
| Cash at End of Period | $20.27B | $14.54B | $13.12B | $10.46B | $5.03B |
| Cash at Beginning of Period | $14.54B | $13.12B | $10.46B | $5.03B | $3.87B |
| Operating Cash Flow | $7.64B | $1.27B | $4.22B | $3.43B | $3.82B |
| Capital Expenditure | $-1.48B | $-1.99B | $-1.66B | $-554.33M | $-561.35M |
| Free Cash Flow | $6.16B | $-726.91M | $2.55B | $2.88B | $3.26B |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.19B | $2.06B | $1.37B | $828.66M | $1.17B | $1.07B | $1.24B | $732.91M | $1.05B | $882.38M | $1.24B | $323.02M | $1.54B | $1.17B | $1.50B | $2.07B | $1.60B | $1.35B | $1.32B | $1.59B |
| Depreciation and Amortization | $- | $212.41M | $212.41M | $222.45M | $-303.45M | $174.52M | $174.52M | $165.40M | $165.40M | $156.68M | $156.68M | $144.28M | $144.28M | $128.81M | $128.81M | $448.39M | $-257.59M | $257.59M | $- | $618.52M |
| Deferred Income Tax | $- | $- | $- | $-2.36B | $570.63M | $-197.17K | $- | $2.87B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $109.87M | $- | $166.66M | $-100.05M | $100.05M | $- | $29.20M | $- | $- | $- | $143.80M | $-330.74M | $330.74M | $- | $312.82M | $-37.00M | $37.00M | $- | $184.42M |
| Change in Working Capital | $- | $-2.36B | $- | $2.22B | $-186.22M | $186.22M | $- | $-2.34B | $1.22B | $-1.22B | $- | $-1.25B | $1.17B | $-1.17B | $- | $-3.25B | $-218.21M | $218.21M | $- | $-3.29B |
| Accounts Receivables | $- | $-2.55B | $- | $2.04B | $-138.97M | $138.97M | $- | $-2.28B | $1.24B | $-1.24B | $- | $-868.27M | $978.59M | $-978.59M | $- | $-3.49B | $-521.21M | $521.21M | $- | $-2.89B |
| Inventory | $- | $77.84M | $- | $129.11M | $-47.25M | $47.25M | $- | $-52.68M | $-19.99M | $19.99M | $- | $-631.22M | $571.97M | $-571.97M | $- | $-173.62M | $329.79M | $-329.79M | $- | $-581.70M |
| Accounts Payables | $- | $- | $- | $- | $90.05M | $-90.05M | $- | $-34.98M | $8.89M | $-8.89M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $109.87M | $- | $55.47M | $-90.05M | $90.05M | $- | $34.98M | $-8.89M | $8.89M | $- | $253.16M | $-384.37M | $384.37M | $- | $414.48M | $-26.79M | $26.79M | $- | $182.33M |
| Other Non Cash Items | $372.68M | $-46.04M | $-114.33M | $2.28B | $287.11M | $1.13B | $-174.52M | $-732.91M | $-1.38B | $877.15M | $-1.09B | $633.48M | $-1.54B | $-1.17B | $-1.50B | $-2.07B | $-1.60B | $-1.35B | $-1.32B | $-1.59B |
| Net Cash Provided by Operating Activities | $1.56B | $1.80B | $1.25B | $3.33B | $1.43B | $2.66B | $1.24B | $732.91M | $1.05B | $697.37M | $148.06M | $720.39M | $2.07B | $1.35B | $249.70M | $-554.59M | $609.92M | $1.83B | $1.54B | $1.43B |
| Investments in Property Plant and Equipment | $-559.99M | $-403.65M | $-561.02M | $-113.32M | $-385.20M | $-600.49M | $-384.79M | $-457.56M | $-55.47M | $-779.36M | $-699.79M | $-335.42M | $-607.30M | $-423.02M | $-298.89M | $-191.72M | $-227.65M | $-79.47M | $-55.49M | $-258.31M |
| Acquisitions Net | $2.33M | $4.24M | $0 | $0 | $8.87M | $1.74M | $2.62M | $337.23M | $17.02M | $1 | $1 | $26.41M | $607.86M | $437.48M | $299.57M | $193.98M | $227.84M | $80.27M | $55.79M | $257.71M |
| Purchases of Investments | $- | $-400.00M | $-200.00M | $-14.92M | $-8.87M | $-106.23K | $-2.06M | $-1.74B | $-622.23M | $-2.68B | $-2.41B | $-5.24B | $-1.12B | $-2.08B | $-4.76B | $-9.27B | $-10.56B | $-6.17B | $-1.63B | $-19.86B |
| Sales Maturities of Investments | $207.81M | $26.21M | $9.01M | $106.01M | $615.70M | $937.14M | $1.04B | $1.03B | $3.40B | $1.87B | $3.47B | $4.47B | $1.43B | $1.93B | $6.46B | $9.01B | $10.89B | $6.20B | $3.89B | $19.81B |
| Other Investing Activities | $-7.81M | $-369.55M | $1.62M | $6.95M | $8.87M | $1 | $-1 | $-333.28M | $-15.59M | $50.30M | $568.79K | $409.26K | $-607.30M | $-423.02M | $-298.89M | $-191.72M | $-227.65M | $-79.47M | $-55.49M | $-258.31M |
| Net Cash Used for Investing Activities | $-357.67M | $-799.42M | $-750.39M | $-15.27M | $239.38M | $338.28M | $659.93M | $-1.16B | $2.72B | $-1.53B | $367.20M | $-1.10B | $-288.80M | $-560.33M | $1.40B | $-451.33M | $100.33M | $-52.69M | $2.20B | $-308.03M |
| Debt Repayment | $- | $- | $- | $1.24B | $- | $- | $-1.25B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $110.16M | $-110.16M | $- | $-827.26M | $370.39M | $-370.39M | $- | $-398.03M | $525.08M | $-525.08M | $- | $-274.08M | $- | $-9.17M | $- | $-11.98M | $- | $-11.98M | $- | $-4.63M |
| Dividends Paid | $-1.27B | $- | $- | $-1.02B | $-39.18M | $-980.88M | $-2.60M | $-15.75M | $-999.79M | $- | $- | $- | $- | $-1.07B | $- | $- | $- | $-1.02B | $- | $- |
| Other Financing Activities | $-94.19M | $-10.27M | $-18.13M | $-1.30B | $-428.95M | $-176.14M | $-212.20M | $924.54M | $-2.13B | $536.76M | $-503.59M | $-238.91M | $- | $-759.41M | $- | $373.95M | $797.23M | $12.68M | $- | $55.00M |
| Net Cash Used Provided by Financing Activities | $-1.37B | $-120.43M | $-18.13M | $-54.48M | $-468.13M | $-1.16B | $-1.46B | $1.24B | $-1.59B | $536.76M | $-503.59M | $-238.91M | $- | $-1.08B | $- | $510.38M | $797.23M | $-1.02B | $- | $55.00M |
| Effect of Forex Changes on Cash | $-15.38M | $12.37M | $-18.21M | $-7.16M | $-8.01M | $37.74M | $-10.04M | $-6.25M | $46.41M | $44.99M | $-4.65M | $-15.99M | $7.18M | $-6.63M | $-1.43M | $-85.77M | $-17.07M | $3.37M | $10.38M | $-8.93M |
| Net Change in Cash | $-180.50M | $1.01B | $467.87M | $3.26B | $1.20B | $1.88B | $-600.95M | $-850.77M | $2.51B | $-253.58M | $7.01M | $-632.17M | $1.72B | $-27.38M | $1.60B | $-581.31M | $1.49B | $788.08M | $3.76B | $1.17B |
| Cash at End of Period | $21.46B | $22.31B | $20.74B | $20.27B | $17.01B | $15.82B | $13.94B | $14.54B | $15.39B | $12.87B | $13.13B | $13.12B | $13.75B | $12.03B | $12.06B | $10.46B | $11.04B | $9.55B | $8.77B | $5.03B |
| Cash at Beginning of Period | $21.64B | $21.31B | $20.27B | $17.01B | $15.82B | $13.94B | $14.54B | $15.39B | $12.87B | $13.13B | $13.12B | $13.75B | $12.03B | $12.06B | $10.46B | $11.04B | $9.55B | $8.77B | $5.01B | $3.86B |
| Operating Cash Flow | $1.56B | $1.80B | $1.25B | $3.33B | $1.43B | $2.66B | $1.24B | $732.91M | $1.05B | $697.37M | $148.06M | $720.39M | $2.07B | $1.35B | $249.70M | $-554.59M | $609.92M | $1.83B | $1.54B | $1.43B |
| Capital Expenditure | $-559.99M | $-403.65M | $-561.02M | $-113.32M | $-385.20M | $-600.49M | $-384.79M | $-457.56M | $-55.47M | $-779.36M | $-699.79M | $-335.42M | $-607.30M | $-423.02M | $-298.89M | $-191.72M | $-227.65M | $-79.47M | $-55.49M | $-258.31M |
| Free Cash Flow | $1.00B | $1.40B | $693.58M | $3.22B | $1.05B | $2.06B | $854.32M | $275.35M | $998.59M | $-81.99M | $-551.74M | $384.97M | $1.46B | $927.70M | $-49.18M | $-746.32M | $382.27M | $1.75B | $1.49B | $1.17B |
Jiangsu Hengrui Medicine Dividends
Explore Jiangsu Hengrui Medicine 's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
0.36%
Dividend Payout Ratio
23.70%
Dividend Paid & Capex Coverage Ratio
3.05x
Jiangsu Hengrui Medicine Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.2 | $0.2 | July 12, 2024 | July 11, 2024 | July 12, 2024 | |
| $0.16 | $0.16 | June 08, 2023 | June 07, 2023 | June 08, 2023 | |
| $0.16 | $0.16 | July 05, 2022 | July 04, 2022 | July 05, 2022 | |
| $0.16667 | $0.16667 | June 10, 2021 | June 09, 2021 | June 10, 2021 | |
| $0.23 | $0.15972 | May 25, 2020 | May 22, 2020 | May 25, 2020 | |
| $0.22 | $0.12732 | March 28, 2019 | March 27, 2019 | March 28, 2019 | |
| $0.292 | $0.13 | May 30, 2018 | May 29, 2018 | May 30, 2018 | |
| $0.135 | $0.05008008 | May 31, 2017 | May 26, 2017 | May 31, 2017 | |
| $0.1 | $0.030914 | June 16, 2016 | |||
| $0.1 | $0.02378 | June 15, 2015 | |||
| $0.09 | $0.019456 | May 15, 2014 | |||
| $0.08 | $0.015722 | June 07, 2013 | |||
| $0.09 | $0.016079 | May 29, 2012 | |||
| $0.1 | $0.011911 | April 26, 2011 | |||
| $0.1 | $0.009926 | March 17, 2010 | |||
| $0.1 | $0.008271 | April 30, 2009 | |||
| $0.1 | $0.006893 | April 11, 2008 | |||
| $0.1733 | $0.00919 | April 02, 2007 | |||
| $0.1833 | $0.007477 | July 18, 2006 | |||
| $0.16 | $0.005438 | June 16, 2005 |
Jiangsu Hengrui Medicine News
Read the latest news about Jiangsu Hengrui Medicine , including recent articles, headlines, and updates.
Similar Companies
6
China Tourism Group Duty Free Corporation Limited
601888.SS
Price: $61.82
Market Cap: $120.70B
6
Foshan Haitian Flavouring and Food Company Ltd.
603288.SS
Price: $40.08
Market Cap: $222.27B
Related Metrics
Explore detailed financial metrics and analysis for 600276.SS.